Plasma exchange for urgent apixaban reversal: In a case of hemorrhagic tamponade after pacemaker implantation

Texas Heart Institute Journal

Volumn 42, Issue 4, 2015, Pages 377-380

  Lam, Wilson W ^a,b   Reyes, Meredith A ^b   Seger, John J ^a,b  

^a TEXAS HEART INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulants administration dosage adverse effects antagonists inhibitors therapeutic use; Apixaban; Atrial fibrillation complications drug therapy; Factor Xa inhibitors; Pacemaker, artificial adverse effects; Plasma exchange; Risk factors; Stroke prevention control; Treatment outcome; Warfarin therapeutic use

Indexed keywords

APIXABAN; FIBRINOGEN; HEMOGLOBIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; BRADYCARDIA; CASE REPORT; CATHETER; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIASTOLIC DYSFUNCTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FAINTNESS; FATIGUE; FEVER; HEART AUSCULTATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TAMPONADE; HUMAN; MALE; NAUSEA; PACEMAKER IMPLANTATION; PAROXYSMAL ATRIAL FIBRILLATION; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PLASMAPHERESIS; REMISSION; SICK SINUS SYNDROME; TACHYCARDIA; THORAX PAIN; THORAX RADIOGRAPHY; VERY ELDERLY; ARTIFICIAL HEART PACEMAKER; BLOOD; CARDIAC TAMPONADE; CHEMICALLY INDUCED; HEART PACING; PLASMA EXCHANGE; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

AGED, 80 AND OVER; CARDIAC PACING, ARTIFICIAL; CARDIAC TAMPONADE; ECHOCARDIOGRAPHY; FACTOR XA INHIBITORS; HUMANS; MALE; PACEMAKER, ARTIFICIAL; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PLASMA EXCHANGE; PYRAZOLES; PYRIDONES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84938558775     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: 10.14503/THIJ-14-4424     Document Type: Article

References (17)

1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92.
2. Yates S, Sarode R. Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects. Curr Opin Hematol 2013;20(6):552-7.
3. Polin GM, Zado E, Nayak H, Cooper JM, Russo AM, Dixit S, et al. Proper management of pericardial tamponade as a late complication of implantable cardiac device placement. Am J Cardiol 2006;98(2):223-5.
4. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014;12(3):320-8.
5. You JH. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. J Gen Intern Med 2014;29(3):438-46.
6. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis 2013;106 (6-7):382-93.
7. Nutescu E. Apixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm 2012;69(13):1113-26.
8. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, Frost C. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014;14(2):147-54.
9. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5): 625-51.
10. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010;8(3):149-54.
11. Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013;80(7):443-51.
12. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19(4):446-51.
13. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011;32(2):183-7.
14. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014;111(2): 240-8.
15. Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C. Single-and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [published erratum appears in Clin Pharmacol 2014;6:61]. Clin Pharmacol 2013;5:177-84.
16. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994;23 (6):817-27.
17. Robinson J, Eccher M, Bengier A, Liberman J. Costs and charges for plasma exchange (PLEX) versus intravenous immunoglobulin (IVIg) in the treatment of neuromuscular disease. Neurology 2012;78:PD6.008.